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Abstract
Background: There is a lack of published evidence on the importance of methotrexate (MTX) dose and route of
administration on both its efficacy and adverse events in children with Juvenile Idiopathic Arthritis (JIA). We aimed
to document our clinical practice based on the treat-to-target approach in order to support the concept that better
therapeutic effect achieved with an optimal dose of parenteral MTX is associated with clinically acceptable adverse
effects comparable to those reported for oral treatment.
Methods: Study inclusion criteria were indication of new MTX therapy for active arthritis in confirmed JIA patients
younger than 18 years. Eligible patients were evaluated prospectively every 3 months for 1 year using standardized
instruments for treatment response (American College of Rheumatology Pediatric (ACRPedi) response, Juvenile
Arthritis Disease Activity Score (JADAS) 71, Clinically Inactive Disease (CID)) and adverse events (laboratory monitoring,
Methotrexate Intolerance Severity Score (MISS)). MTX responders had to achieve at least ACRPedi 70 response. MTX
intolerance was defined by MISS≥ 6.
Results: In 45/55 patients (81.8 %) MTX was started as subcutaneous injection. The initial median weekly dose was 14.
4 mg/m2 in parenteral and 11.7 mg/m2 in oral administration. MTX therapy was effective in the level of ACRpedi70
and CID in 50.9 % and 30.9 % of patients at month 6 and in 70.9 % and 56.4 % after 12 months of the treatment,
respectively. MTX intolerance at 6 and 12 months was noted in 25.5 % and 30.6 %, respectively. Management of
intolerance included change in the dose and/or route of administration, education and councelling. Adverse events
led to MTX withdrawal in 5 patients (9 %) due to toxicity (n = 3) and intolerance (n = 2). We did not find any significant
predictive factors for either MTX therapeutic response or intolerance.
Conclusion: Subcutaneous MTX weekly dose around 15 mg/m2 is associated not only with a high response rate
within the first 12 months of treatment, but also with a relatively low rate of significant adverse effects that would
lead to the treatment termination. It allows early recognition of MTX non-responders and addition of biologic therapy.
Sustainability of therapeutic effect and longer-term evolution of adverse events will be addressed by an ongoing
extension of the study.
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Background
Over the last decades low-dose weekly methotrexate
(MTX) has been commonly used in the treatment of ju-
venile idiopathic arthritis (JIA) [1]. It has become an es-
sential component of various clinical guidelines and
recommendations as a first-line disease-modifying drug
for disease unresponsive to nonsteroidals (NSAIDs) and/
or intraarticular corticosteroids [2–4].
MTX efficacy has been reported mainly in polyarticular-
course JIA, though its extent varies [5, 6]. Differences in
drug dosing and route of administration as well as in the
method of efficacy assessment hamper inter-study com-
parisons. Most commonly, American College of Rheuma-
tology Pediatric (ACRpedi) response criteria have been
used to define various levels of therapeutic effect [7]. More
recently, a composite measure of disease activity (Juvenile
Arthritis Disease Activity Index, JADAS) and its cut-off
values for various disease status have been defined [8].
Among factors influencing inter-patient heterogeneity of
treatment response, polymorphisms of genes involved in
MTX metabolic pathways [9–15], disease phenotype and
its previous duration and several biomarkers have been re-
ported [16–20]. Moreover, factors related to MTX absorp-
tion and kinetics have also been shown to influence
treatment efficacy [21–25].
Evaluation of the presence, type and severity of drug
adverse events forms a natural part of therapeutic moni-
toring. Low-dose MTX has a variety of adverse effects.
These include features of MTX antiproliferative effect
which are mostly related to its post-dose concentrations
[26–30]. MTX affects rapidly dividing cells of gastro-
intestinal (GI) tract causing nausea and/or vomiting and
bone marrow leading to cytopenia. Mechanisms of hep-
atic and central nervous system (CNS) toxicity are more
complex and include elevation of liver enzymes, head-
aches and behavioral changes [31, 32]. In addition to
post-treatment complaints anticipatory and associative
symptoms have been described [33–35]. Patients report
presence of gastrointestinal symptoms or behavioral
changes (cry, irritation, refusal to take the drug) already
before or at the time of MTX administration (anticipa-
tory intolerance) or even when just thinking about it
(associative intolerance). They appear to be more
commonly associated with parenteral route of MTX ad-
ministration and often lead to precautious termination
of otherwise safe and effective treatement [36, 37].
Therefore monitoring of MTX adverse events requires
not only regular blood tests for hepatic and marrow tox-
icity, but also directed questioning to detect subjective
complaints.
This study was driven by the lack of published evi-
dence on the importance of MTX dose and route of ad-
ministration on both its efficacy and various types of
adverse events. We aimed to thoroughly document our
clinical practice based on the treat-to-target approach in
order to prove the concept that better therapeutic effect
achieved with the higher dose of parenteral MTX is as-
sociated with clinically acceptable adverse effects com-
parable to those reported in published series using oral
treatment.
Methods
Patients and study protocol
Consecutive patients were recruited prospectively from
the paediatric rheumatology clinic population of the
Department of Paediatrics and Adolescent Medicine, 1st
Faculty of Medicine, Charles University in Prague, be-
tween October 2013 and January 2015.
This was a sub-study of a large project running at the
Unit aim of which was to prospectively collect clinical
data on all consecutive JIA patients starting new treat-
ments for active disease. The project was approved by
the Local Research Ethics Committee of the General
University Hospital in Prague and informed consent was
obtained from the patients and/or their legal guardians,
as appropriate. To become eligible patients must have
had a definitive diagnosis of JIA according to the ILAR
criteria [38] and exhibit active disease requiring either
initiation of treatment for new-onset JIA or for the dis-
ease relapse. Active disease was defined by the presence
of at least one joint with synovitis. Treatment options
were: intra-articular triamcinolone hexacetonide, MTX,
sulphasalazine, TNF-inhibitors and tocilizumab. At our
Unit the treatment plan guided by the recently published
ACR recommendations [2, 3] is always individually tai-
lored to patient needs according to the treating phys-
ician. Only patients starting the MTX treatment are
included in this report. The MTX therapeutic strategy is
based on the following principles: 1. Early start, 2. MTX
dose around 15 mg/m2/week administered parenterally
using pre-filled syringes (MTX concentration 50 mg/ml),
3. Folic acid supplementation 5–10 mg once weekly 24–
48 h after MTX dose, 4. The same dose which has in-
duced disease inactivity is maintained for the minimum
of 1 year if no clinically significant adverse events occur.
Non-responders at 3–6 months change their treatment,
usually by adding a biologic drug. Oral MTX in one
weekly single dose is rarely considered in older children
with relatively mild disease. Clinical and laboratory data
and patient-reported outcomes are recorded within the
interval of ± 2 weeks of the first MTX administration
and then in 3-monthly intervals.
Assessment of treatment efficacy
Treatment effect was evaluated by using two standard-
ized methodologies for JIA activity assessment: ACR
Pedi (The American College of Rheumatology) and
JADAS (the Juvenile Arthritis Disease Activity Score).
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ACR Pedi uses the core-set of 6 disease activity variables
(active joint count, limited joint count, physician global
assessment of disease activity, parent/patient global as-
sessment of the patient's well-being, Childhood Health
Assessment Questionnaire and ESR/CRP) on 2 distinct
occasions resulting in the defined improvement rates of
ACR Pedi 30, 50, 70 and 90. These rates are defined as
improvement of at least 3 out of 6 variables by a mini-
mum of 30, 50, 70 or 90 % and no more than one of the
resulting ones deteriorating by more than 30 % [7].
Good clinical response to MTX was defined as reaching
the minimum of ACR Pedi 70. JADAS is a numeric
score resulting from the values of 4 measures: active
joint count (from 10, 27 or 71 joints), physician's global
assessment of disease activity (10 cm VAS), parent/pa-
tient global assessment of overall well-being (10 cm
VAS) and normalized ESR rate (0–10) [8]. JADAS-71
(score range 0–101) was chosen for this study. Addition-
ally, disease state at 6 and 12 months was assessed ac-
cording to the JADAS cutoff values as inactive disease
(≤1) or minimally active disease (≤2 for oligoarthritis
and ≤3.8 for polyarthritis) and high disease activity (4.2
for oligoarthritis and 10.5 for polyarthritis) [39–42].
Complete treatment response was also defined apply-
ing the Wallace criteria as the presence of inactive dis-
ease (clinically inactive disease, CID). CID is defined by
an absence of active synovitis or other active JIA features
(incl. uveitis, fever, rash, serositis, hepatosplenomegaly,
lymhadenopathy attributable to JIA), normal ESR or
CRP, the lowest possible physician global evaluation of
disease activity and absence of significant morning stiff-
ness (duration ≤15 min) [43–45].
Assessment of MTX treatment adverse events
For the purpose of this study MTX adverse events were
divided into toxicity and intolerance. Toxic adverse
events were further assessed as measurable toxicity
(increase of at least one liver transaminase above 2-
times of upper normal limit (ULN) or significant cytope-
nia or anaemia) and patient-reported toxicity defined as
patient complaints developing after MTX administration
(gastrointestinal symptoms - abdominal pain, nausea,
vomiting, oral ulcers, injection site reaction). Condi-
tioned response to MTX-associated toxicity was defined
as anticipatory intolerance when gastrointestinal (GI)
complaints were present at the time of MTX administra-
tion, associative intolerance was considered when GI com-
plaints occurred when thinking about MTX administration.
On top of that behavioral symptoms at the time of
MTX administration were also recorded. Patient-
reported symptoms were captured at every visit using
the Czech adaptation of the Methotrexate Intolerance
Severity Score (MISS), which defines MTX-intolerant
patient by the presence of at least 6 out of 36 points
with at least 1 point on anticipatory and/or associative
and/or behavioral symptoms [34].
Statistical analysis
Continuous and categorical variables were described
using median with 25th and 75th percentile and relative
frequencies. Mann–Whitney U test was used when
assessing statistical significance of difference in continu-
ous variables between two groups (when comparing
more than two samples Kruskal-Wallis test with post-
hoc Bonferroni correction was applied). Statistical sig-
nificance of dependence between categorical variables
was assessed with Fisher exact test. Time to treatment
response was analyzed using Kaplan-Meier survival ana-
lysis method. Univariate logistic regression model was
applied to measure association of baseline characteristics
with occurrence of MTX intolerance (or treatment re-
sponse). Level of statistical significance was set to 0.05
in all analyses.
Results
Characteristics of the patient cohort
Total of 107 patients fulfilled the study inclusion criteria
during the 16-month recruitment period. In 58 children
MTX therapy was initiated. Out of them 55 expressed
their consent with the study participation. Their charac-
teristics are summarized in Table 1. Their median age at
study entry was 5.3 years (IQR 2.8;10.6), at disease onset
4.8 years (IQR 2.2; 10.0), disease duration was 3.8 months
(IQR 2.5;6.4). The distribution of JIA ILAR onset sub-
types at study entry was: oligoarthritis 38.2 % (N = 21)
(persistent 32.7 % (N = 18), extended 5.5 % (N = 3)),
polyarthritis 45.5 % (N = 25), enthesitis- related arthritis
5.5 % (N = 3), psoriatic arthritis 1.8 % (N = 1), systemic
arthritis 9.1 % (N = 5). New onset disease was present in
48 patients (87.3 %), 7 patients had disease relapse. In
these patients median interval from the previous medi-
cation withdrawal to the relapse was 10.5 months (IQR
6.0; 15.0). Median initial JADAS score was 12.0 (IQR 8.5;
20.2) reflecting active disease with the median number
of joints with active arthritis of 5 (IQR 3; 6). High dis-
ease activity (JADAS cutoff values 4.2 for oligoarthritis
and 10.5 for polyarthritis) was present in 40 children
(72.7 %). Median JADAS in those who developed
polyarticular course of the disease (regardless JIA onset
subtype, N = 45) was 14 (ICQ 10.0; 20.4), patients with per-
sistent oligoarthritis (at 12 months of follow-up, No =10)
had median JADAS of 5.6 (ICQ 5.0; 8.5). Concomitant
medication at the start of MTX therapy included systemic
(oral) corticosteroids in 9 patients (16,4 %) (for systemic
symptoms n = 4, resistant uveitis n = 3, severe polyarthritis
n = 2) and intraarticular corticosteroids (within 1 month be-
fore or after MTX start) in 21 patients (38,2 %).
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MTX therapy
In 45 patients (81,8 %) MTX was started as once weekly
subcutaneous injection, 10 patients received oral tablets
(Table 1). There was no significant difference in demo-
graphic or disease parameters between the groups apart
from the age at MTX start which was higher in patients
starting oral treatment (median 14,0 years (IQR 11.8;
15.9) when compared to patients treated parenterally
(median 4,1 years (IQR 2.6; 7.8) (p < 0,001). Parenteral
MTX was administered in the median weekly dose of
14.4 mg/m2 (IQR 13.3; 15.9), oral MTX dose was 11.7
(8.3; 12.5) (p < 0,001).
Table 2 summarizes treatment changes, their timing
and respective disease activity during the follow-up.
MTX dose (median (IQR)) was increased from 12.1
(11.1; 13.7) mg/m2 at study entry to 14.9 (13.6; 15.6) and
13.8 (12.4; 15.8) mg/m2 at 6 and 12 months, respectively,
in 18 patients (32.7 %). In 20 children (36.4 %) it was de-
creased from 14.3 (12.4; 16.1) to 13.7 (12.2; 15.2) and
10.5 (8.8; 12.8) mg/m2 at 6 and 12 months, respectively.
Other treatment modifications included change in the
route of administration (n = 13; 23.6 %), withdrawal (n =
5; 9.1 %), addition of biological therapy (n = 14; 25.5 %).
Increased dose and change from oral to parenteral appli-
cation were always due to the persistence of active dis-
ease. On the other hand, change from parenteral to oral
administration and MTX dose reduction were triggered
by combinations of MTX toxicity and intolerance on the
background of the decreasing disease activity (Table 2).
Treatment changes resulted in the median MTX dose of
14.2 mg/m2 (IQR 13.1;15.4) at 6 months and 13.7 mg/
m2 (IQR 11.5;14.4) at 12 months for the whole cohort.
At month 12 from 50 patients who were still receiving
MTX only 9 had oral tablets.
All 14 patients who received biologic therapy either
failed to achieve ACRpedi50 response (n = 11) and/or
had resistant uveitis (n = 4). Their median JADAS71 at
the time of treatment change was 15.8 (ICQ 6.50; 13.00).
Addition of biologics (etanercept = 8, adalimumab = 4,
tocilizumab = 2) occured after the median duration of
MTX therapy of 3.8 (ICQ 4.0; 8.8) months.
Treatment efficacy and disease activity assessments
MTX therapy was effective in the level of ACRpedi70
and 90 in 50.9 % and 42.9 % of patients at month 6 and
in 70.9 % and 63.6 % after 12 months of the treatment,
respectively. Clinically inactive disease was reached in 17
(30.9 %) patients at month 6 and in 31 (56.4 %) patients
at month 12. There was no difference in the time to
inactivity between various JIA subtypes. Patients who re-
ceived biologics (n = 14) were considered non-
responders to MTX from the time point of starting the
biologic including 4 children who achieved CID after
Table 1 Characteristics of 55 patients at study entry
Female n(%) 38 (69.1)
New onset n(%) 48 (87.3)
Age at onset (years) median (IQR) 4.8 (2.2; 10.0)
Age at MTX start (years) median (IQR) 5.3 (2.8; 10.6)




– Oligoarthritis: persistent/extended 18/3 (32.7 %/5.5 %)
– Polyarthritis (RF positive n = 1) 25 (45.5 %)
– Systemic with polyarthritis 5 (9.1 %)
– Enthesitis-related 3 (5.5 %)
– Psoriatic 1(1.8 %)
Parent/patient global assessment of well-being
mm, median (IQR)
27 (15; 40)
CHAQ 0–3 median (IQR) 0.25 (0.13; 0.69)
ESR mm/h median (IQR) 23 (15; 35)
MTX dose mg/m2 /week median (IQR) 14.2 (12.1;15.2)
– s.c. (n = 45) 14.4 (13.3; 15.9)
– p.o. (n = 10) 11.7 (8.3; 12.5)
Concomitant therapy n(%)
– IATHa 21 (38.2)
– Sulphasalazine 1 (1.8)
– Systemic corticosteroids 9 (16.4)
– Folic acid 5–10 mg/weekb 55 (100)
aWithin 1 month prior to or after MTX start
bOnce weekly dose 24–48 hours post-MTX administration
MTX, Methotrexate
IATH, Intraarticular triamcinolone hexacetonide
CHAQ, Childhood Health Assessment Questionnaire
Global assessments in mm on the 100 mm visual analogue scale
Table 2 Changes in the treatment during the follow-up
N (%) Time from MTX onset (months)a JADAS71 at the time of changea
↑MTX dose 18 (32.7) 3.0 (3.0; 6.0) 7.0 (4.5; 11.5)
↓MTX dose 20 (36.4) 7.5 (6.0; 9.0) 0.5 (0.0; 2.5)
Change in route of administration 13 (23.6) 6.0 (4.0; 12.0) 2.0 (0.4; 9.9)
Withdrawal 5 (9.1) 9.0 (8.0; 9.0) 3.0 (0.0; 6.5)
Addition of biologic 14 (25.5) 3.8 (4.0; 8.8) 15.8 (6.5; 13.0)
avalues are medians (interquartile range)
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biologic medication was added to MTX who were ex-
cluded from the evaluation of disease inactivity. Total of
61.8 % patients reached low disease activity according to
published JADAS cutoff values for oligo and polyarthri-
tis (Table 3).
Table 3 shows evolution of therapeutic response dur-
ing 1-year follow-up as expressed by different disease
activity measures. There was no significant difference in
the proportion of patients who reached high levels of
response when measured by either JADAS value (=0) or
by fullfilling the CID criteria. Neither the rate or extent
of therapeutic response were influenced by JIA onset
subtype or by the route of MTX administration (data
not shown). Figure 1 illustrates treatment response as
expressed by JADAS71 values in persistent oligoarthritis
and polyarticular-course JIA patients. Logistic regression
analysis of demographic data, disease and treatment
characteristics did not reveal any variable that would sig-
nificantly influence the likelihood of therapeutic re-
sponse (data not shown).
MTX toxicity and intolerance
During the 12 month follow-up measurable toxicity of
MTX was recorded in 8 patients (15.4 %): elevation of
transaminases in 7 patients and cytopenia in 1 patient.
In 3 cases these adverse events led to MTX withdrawal
while in the remaining 5 children results normalised
after the short treatment interruption or MTX dose re-
duction. None of the patients reported significant oral
ulcers or injection site reaction.
Presence of patient-reported GI toxicity, associative/
anticipatory intolerance and behavioral symptoms is
summarized in Table 4. Only 11/55 patients (20 %) re-
ported no adverse events throughout the observational
period (MISS = 0 at every visit). Intolerance (MISS ≥ 6)
slowly developed during the initial months of the treat-
ment and was present in the maximum of 25.5 % of
patients at 6 months and remained relatively stable
thereafter (30.6 % at 12 months). This cut-off MISS
value for the definition of intolerance was reached at
least once in 25/55 children (45.5 %). Concomitant treat-
ment with biologics did not have any significant impact
on the MISS at 12 months (data not shown). In the ma-
jority of cases intolerance was managed to the patient
and family satisfaction by treatment modifications and
various other actions and their combinations: change in
the route and/or timing of MTX administration, MTX
dose reduction, addition of antiemetics, councelling.
MTX withdrawal was the ultimate solution in 2 patients
only (8 %).
Behavioral symptoms were noted in at least one cat-
egory in all intolerant patients, but they were present
also in 27 (49 %) patients with the MISS lower than 6,
regardless the route of MTX administration. The mean
MTX dose in intolerant patients was not significantly
different from that of tolerant ones (14.2 vs 13,4 mg/m2,
OR (95 % CI) = 1,15(0.94;1,40), p = 0,612) (Table 5).
There were no serious adverse events (e.g. infections,
pulmonary toxicity) that would require hospital admis-
sion throughout the study period. Logistic regression
analysis did not demonstrate any significant associations
of MTX intolerance with the patient, disease and treat-
ment variables (Table 6). There was a trend towards in-
creased odds for MTX intolerance in patients treated
with parenteral MTX (OR (95 % CI) = 2,44 (0,56;10,65),
p = 0,236), polyarticular-course of JIA (OR (95 % CI) =
1,43 (0,36; 5,78), p = 0,612) and higher age at MTX start
(OR (95 % CI = 1,45 (0,48; 4,47), p = 0,505). Potential
predictive factors of good MTX tolerance were higher
CHAQ values, shorter interval from disease onset to
treatment and male gender (Table 6).
Discussion
We have reported disease outcome in a single-centre co-
hort of patients with early JIA (median disease duration
3.8 months) during the first 12 months of MTX treat-
ment. This prospective observational study was triggered
by the lack of published evidence on the advantages of
the parenteral versus oral route of MTX administration
during the induction of remission therapy of JIA. Not-
ably, we documented treatment efficacy using up-to-date
standard disease assessments along systematic evaluation
of MTX adverse events including conditioned effects like
associative and anticipatory intolerance. We have shown
that subcutaneous MTX weekly dose around 15 mg/m2
is associated not only with a response rate of ACRpedi
70 in over 70 % of patients, but also with a very low rate
Table 3 Evolution of the treatment response expressed by different standardised measures
F/U (months) ACRpedi70 (%) ACRpedi90 (%) JADAS inactive (%) JADAS low activity (%) CID (%)
3 28.6 12.7 5.5 21.8 9.1
6 50.9 42.9 32.7 47.2 30.9
9 56.4 50.9 43.6 54.5 47.2
12 70.9 63.6 56.4 61.8 56.4
F/U, Follow-up visit; CID, Clinically Inactive Disease [40]
Results for 55 patients are shown. Patients who received biologics and/or who withdrew MTX were considered non-responders from the time point of starting the
biologic or stopping MTX
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of significant adverse effects that would lead to the treat-
ment termination.
An advent of cytokine inhibitors as well as better
handling of standard JIA treatments like MTX have
shifted our therapeutic target from reduction of disease
activity to its complete elimination defined as disease in-
activity and remission [46, 47]. With the constantly
growing body of evidence on the biology of chronic arth-
ritis it has become evident that time plays an important
role in our ability to induce disease inactivity: The
shorter disease duration before treatment onset and the
more intensive therapeutic regimen used, the bigger is
the chance to achieve sustained remission [19, 46, 47].
Such a treat-to-target approach has changed the way we
use MTX now from the slow dose-escalation regime to
the more aggressive treatment using the optimal effect-
ive dose established by Ruperto et al. at 15 mg/m2 [33]
from the very beginning. Moreover, pharmacokinetic
studies suggesting better bioavailability of parenteral
against oral MTX [25, 26] have led us to starting MTX
treatment in majority of patients in the form of subcuta-
neous injections. This approach allows for early assess-
ment of the patient's potential to respond to treatment
and to introduce biologic therapy in non-responders as
early as within 3–6 months from starting MTX.
Indeed, in our cohort of 55 patients starting MTX only
10 (18.2 %) received oral tablets. The difference in the
initial MTX dose and route of administration from some
recently published series is illustrated in Table 7. Treat-
ment response at 6 and/or 12 months is expressed by
the percentage of patients achieving ACRpedi70 and/or
CID. Proportion of MTX responders at 6 months is
similar across most of the studies ranging from 38 to
56 % of patients [33, 44–53], similar to our results. Only
a few studies provide information on the rate of inactive
disease [43]. The higher rate of CID in our cohort
(30.9 %) at 6 months when compared to the studies by
Ruperto et al. (12 %) [33] and Wallace et al. (23.3 %)
[43] could be explained by higher MTX dose and shorter
prior disease duration in our patients. Although the dose
of 15 mg/m2 is close to 0.5 mg/kg in older children, dos-
ing per body weight unit in younger individuals ends up
with a lower calculated dose. We believe these reasons
together with the parenteral route of MTX administra-
tion apply also to the higher rate of responders in our
cohort after 1 year of parenteral MTX therapy which
exceeded 70 % of patients with the total of 56.4 % reach-
ing CID (Table 3). Additionally, the variability of results
in different studies also reflects differences in their de-
sign (retrospective analysis from the registry, prospective
observational, prospective treatment trial).
Multiple studies have dealt with potential biomarkers
of response to MTX that could inform our therapeutic
decision-making and lead to early introduction of other
Fig. 1 Treatment response expressed by JADAS in polyarticular-course and persistent oligoarticular JIA
Table 4 Evolution of gastrointestinal toxicity, anticipatory/associative intolerance and behavioral symptoms
Months na MISS O MTX intolerance Anticipatory and/or associative symptoms Gastrointestinal toxicity Behavioral symptoms
n (%) n (%) n (%) n (%) n (%)
3 53 19(3.8 %) 10 (18.5 %) 11 (20.8 %) 16 (30.2 %) 31 (58.5 %)
6 54 13 (24.1 %) 14 (25.5 %) 16 (29.6 %) 25 (46.3 %) 33 (66.1 %)
9 49 17 (34.7 %) 14 (28.0 %) 13 (26.5 %) 20 (40.8 %) 27 (55.1 %)
12 49 18 (36.7 %) 15 (30.6 %) 9 (18.4 %) 16 (32.7 %) 28 (57.1 %)
MISS, Methotrexate Intolerance Severity Score
aMISS not available for 2 patients at Month 3. In subsequent months numbers reduced by patients who withdrew (n = 5), in 1 patient MISS at 9 and 12 months
not available
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Table 5 Overall and per domain prevalence of MTX- related gastrointestinal and behavioral adverse events at 6 months





(MISS 0–5) (MISS≥ 6)
Number of patients n = 54 n = 40 n = 14 n = 47 n = 7
Cutoff score≥ 6 14 (25,9 %) 0 (0,0 %) 14 (100,0 %) 12 (25,5 %) 2 (28,6 %) 1
Cutoff score = 0 13 (24,1 %) 13 (32,5 %) 0 (0,0 %) 12 (25,5 %) 1 (14,3 %) 1
Anticipatory ± associative symptoms 16 (29,6 %) 7 (17,5 %) 9 (64,3 %) 14 (29,8 %) 2 (28,6 %) 1
Gastrointestinal toxicity 25 (46,3 %) 14 (35,0 %) 11 (78,6 %) 20 (42,6 %) 5 (71,4 %) 0,229
Behavioral symptoms 33 (61,1 %) 19 (47,5 %) 14 (100,0 %) 29 (61,7 %) 4 (57,1 %) 1
Abdominal pain 20 (37,0 %) 9 (22,5 %) 11 (78,6 %) 18 (38,3 %) 2 (28,6 %) 1
- after MTX 15 (27,8 %) 7 (17,5 %) 8 (57,1 %) 13 (27,7 %) 2 (28,6 %) 1
- anticipatory 6 (11,1 %) 2 (5,0 %) 4 (28,6 %) 6 (12,8 %) 0 (0,0 %) 1
- associative 4 (7,4 %) 1 (2,5 %) 3 (21,4 %) 4 (8,5 %) 0 (0,0 %) 1
Nausea 25 (46,3 %) 15 (37,5 %) 10 (71,4 %) 21 (44,7 %) 4 (57,1 %) 0,692
- after MTX 21 (38,9 %) 12 (30,0 %) 9 (64,3 %) 17 (36,2 %) 4 (57,1 %) 0,411
- anticipatory 8 (14,8 %) 1 (2,5 %) 7 (50,0 %) 8 (17,0 %) 0 (0,0 %) 0,577
- associative 9 (16,7 %) 4 (10,0 %) 5 (35,7 %) 7 (14,9 %) 2 (28,6 %) 0,33
Vomiting 5 (9,3 %) 2 (5,0 %) 3 (21,4 %) 5 (10,6 %) 0 (0,0 %) 1
- after MTX 5 (9,3 %) 2 (5,0 %) 3 (21,4 %) 5 (10,6 %) 0 (0,0 %) 1
- anticipatory 2 (3,7 %) 1 (2,5 %) 1 (7,1 %) 2 (4,3 %) 0 (0,0 %) 1
Behavioral symptoms 33 (61,1 %) 19 (47,5 %) 14 (100,0 %) 29 (61,7 %) 4 (57,1 %) 1
- restlessness 25 (46,3 %) 13 (32,5 %) 12 (85,7 %) 22 (46,8 %) 3 (42,9 %) 1
- crying 24 (44,4 %) 13 (32,5 %) 11 (78,6 %) 22 (46,8 %) 2 (28,6 %) 0,443
- irritability 21 (38,9 %) 8 (20,0 %) 13 (92,9 %) 19 (40,4 %) 2 (28,6 %) 0,693
- refusal of MTX 14 (25,9 %) 5 (12,5 %) 9 (64,3 %) 13 (27,7 %) 1 (14,3 %) 0,662
Table 6 Potential predictors of MTX intolerance (MISS≥ 6)
MISS intolerance
OR (95 % CI)a p-value
Male 0,70 (0,22; 2,22) 0,546
Age at onset (by 10 yrs) 1,61 (0,51; 5,02) 0,416
Age at MTX start (by 10 yrs) 1,46 (0,48; 4,47) 0,505
Interval from onset to MTX start (by 10 months) 0,41 (0,10; 1,58) 0,194
Uveitis before MTX treatment 0,87 (0,21; 3,67) 0,853
ANA positive 1,49 (0,51; 4,37) 0,465
Active joints (by 10 joints) 1,01 (0,55; 1,84) 0,979
Joints with limitation of motion (by10 joints) 1,12 (0,63; 1,98) 0,695
Physician global assessment of disease activity (by 10 mm) 1,22 (0,87; 1,69) 0,245
Parent/patient global assessment of well-being (by 10 mm) 0,88 (0,68; 1,14) 0,328
FW (by 10 mm/h) 1,26 (0,95; 1,67) 0,111
CRP (by 10 mg/l) 1,09 (0,89; 1,34) 0,409
CHAQ 0,30 (0,08; 1,17) 0,083
JADAS 71(á 10 points) 1,12 (0,68; 1,82) 0,659
Parenteral form of methotrexate 2,44 (0,56; 10,65) 0,236
Initial MTX dose (mg/m2) 1,15 (0,94; 1,40) 0,181
Polyarticular form of JIA 1,43 (0,36; 5,78) 0,612
aOR = odds ratio, 95 % IS = 95 % confidence interval
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treatments in suspected non-responders, reviewed by
Dijkhuizen [5]. Among these high serum concentration
of MRP8/14 protein at baseline [51] and long-chain
MTX polyglutamates at 3 months of the treatment [52]
predicted a favourable response to MTX. From genetic
factors single-nucleotide polymorphisms of genes involved
in MTX metabolic pathways and some novel candidate
genes have been suggested, though their relevance is yet
to be confirmed [53–55].
The spectrum of adverse events of MTX therapy has
expanded by the recognition and systematic evaluation
of so called conditioned response in the form of antici-
patory and associative intolerance [34, 35, 56–58]. In
this study we have attempted to distinguish toxic adverse
events limited to laboratory changes and post-dose GI
symptoms from the intolerance featuring GI symptoms
around MTX administration (anticipatory) and when
thinking about MTX (associative) using a previously val-
idated scoring system MISS [34] (Table 5). In addition,
behavioral symptoms at MTX administration were also
systematically recorded.
Proportion of patients who featured measurable toxic
adverse events of transaminase elevation and/or cytope-
nia was similar to published series [32, 58–60] and was
mild and easy to manage in most cases. Presence of
patient-reported GI toxicity as well as intolerance and
behavioral symptoms were frequent (Table 4). MTX in-
tolerance (MISS ≥ 6) in at least one visit during the
12 months of treatment was recorded in 45.5 % of our
patients. This figure is similar to that reported by
Bulatovič and van Dijkhuizen (50.5 % and 41.5 %, re-
spectively) despite the fact that our patients received
higher MTX doses (14.2 mg/m2 versus 10.2 and 9.9 mg/
m2, respectively) administered parenterally in most cases
[5, 34]. This finding does not support the presence of
direct relationship between MTX dose and route of ad-
ministration and its intolerance. This is in agreement
with our previous observation where higher doses of
MTX associated with increased intracellular MTX con-
centrations did not lead to an increased rate of MTX
toxicity [15].
Severity of MTX intolerance is difficult to assess due
to the subjective nature of patient-reported symptoms.
Therefore we believe that an impact of reported adverse
events on the treatment itself should serve as the main
measure of their clinical significance. Despite the high
frequency of complaints in our study they eventually led
to MTX withdrawal in 2 patients only. It is our impres-
sion that this favourable outcome was associated with
the systematic approach to MTX-related complaints in
our clinics. MISS form was administered along other
patient-reported questionnaires to every patient at rou-
tine follow-up visits by the nurse specialist who checked
its completion and then discussed with the treating
physician who reviewed the ticked items with the patient
and/or the accompanying parent and suggested potential
solutions tailored to the individual patient characteristics
and needs. These discussions covered also the analysis of
the risk/benefit ratio of MTX therapy and re-assessment
of the future treatment plan. Such a systematic parent/





MTX dose (route) ACRpedi70 (%)/CID (%)
Treatment duration (months)
6 12
Ruperto 2004 [33] 595 2.7 yrs (mean) 10 ± 2.3 mg/m2 (78 % p.o.) 38/12b
40 14.5 ± 1.3 mg/m2 (s.c., i.m.)a 45/12.5b
40 28.5 ± 2.5 mg/m2 (s.c., i.m.)a 47.5/10b
Bartoli 2007 [61] 125 1.45 yrs (med) 10 mg/m2 (NA) 26.4/NA
Tynjala 2011 [62]c 20 1.5 mo (mean) 15–30 mg/m2 (p.o.,s.c.) 60/25
Klein 2012 [50] 259 1.1 yrs (med) 0,4 mg/kg (p.o.) 51/NA 66/NA
152 0.8 yrs (med) 0.42 mg/kg (s.c.) 53/NA
Bulatovič 2012 [13] 104 ≥1 yrs 9.8 mg/m2 (NA) 38.5/NA 50/NA
Wallace 2012 [43] 43 5.2 mo (mean) 0.5 mg/kg (s.c.) NA/23.3 NA/16.3
Moncrieffe2013 [51] 87 1.3 yrs (med) 10–15 mg/m2 (70 % p.o.) 56.3/NA
Pastore 2015 [53] 69 1.0 yrs (med) 15 mg/m2 (62 % p.o.) 52.2/NA
Fraňova 2016 55 3.5 mo (med) 14.2 mg/m2 (18 % p.o.) 50.9/30.9 70.9/56.4
MTX, Methotrexate
CID, Clinical Inactive Disease [40]
NA, Not available
aPatients were non-responders to the dose of 10 ± 2.3 mg/m2 after the first 6 months
bCriteria for inactive disease: Absence of active arthritis and ESR < 20 mm/h
cDose 15 mg/m2 orally, non-responders at 3 months switched to 30 mg/m2 s.c
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patient education and re-assurance served as an add-
itional component of intolerance management. In the
light of the massive evidence on the efficacy and toler-
ance of biologics, MTX adverse effects are becoming
more visible than 20 years ago when therapeutic options
for JIA were limited. Moreover, incorporation of patient-
reported outcomes into the routine disease assessment
has led to better appreciation of an impact of subjective
complaints including drug intolerance on the patient
and family health-related quality of life.
The relatively short duration of follow-up reported
here did not allow for assessment of the sustainability of
treatment response as well as the long-term evolution of
adverse events. Moreover, direct comparison of treat-
ment efficacy and adverse events between patients
treated with oral versus parenteral MTX was not pos-
sible due to relatively small numbers of patients, mainly
those treated orally. Small patient number also contrib-
uted to the inability to detect any significant variables
associated with either treatment response or presence of
adverse events (Table 6). Although JIA treatment strat-
egy has been established at our Unit the study retained
an observational character where therapy was based on
the treating physician's decision. Therefore systematic
stratification of patients into more homogeneous treat-
ment groups that would improve our ability to analyze
treatment variables was not possible.
Conclusions
As long as the reliable and widely accessible system of
prediction of MTX efficacy and intolerance is not avail-
able, optimal clinical approach to MTX therapy remains
of upmost importance. This study brings additional evi-
dence for the high efficacy of MTX especially in early
disease and underlines importance of using the dose
around 15 mg/m2 administered parenterally in order to
evaluate treatment response early in the disease course.
Such a treatment strategy does not appear to increase
the rate and severity of MTX adverse events when com-
pared to oral treatment using lower doses. Limited by
short duration of follow-up and relatively small patient
number true significance of our findings has yet to be
confirmed through the ongoing extension of the study.
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